Roivant Sciences (ROIV)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$38.23+6.08%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ROIV
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||
| Revenues | 7.5 | 8.3 | 8.3 | 29.1 | 31.5 | 55.3 | 23.8 | — |
| Operating Expenses & Income | ||||||||
| Selling, General & Admin | — | — | — | — | 600.5 | 775.0 | — | — |
| R&D Expenses | 730.9 | 681.8 | 681.8 | 550.4 | 454.1 | 483.0 | 236.6 | — |
| Operating Income | (596.1) | (515.1) | (515.1) | (1,003.3) | (906.8) | (1,351.6) | (1,070.9) | — |
| Earnings from Continuing Operations | ||||||||
| Interest Expense | — | — | — | — | 28.0 | 7.0 | 2.8 | — |
| Interest & Investment Income | 166.7 | 178.1 | 178.1 | — | — | — | — | — |
| Asset Writedown | — | 17.1 | 17.1 | — | — | — | — | — |
| EBT, Incl. Unusual Items | (289.9) | (264.6) | (264.6) | (681.6) | (885.0) | (923.7) | (898.5) | — |
| Income Tax Expense | 124.7 | 133.3 | 133.3 | 48.2 | 4.1 | 0.4 | 1.7 | — |
| Earnings from Continuing Operations | (414.6) | (397.9) | (397.9) | (729.8) | (889.1) | (924.1) | — | — |
| Net Income | ||||||||
| Minority Interest | (148.3) | (98.1) | (98.1) | (184.8) | (106.4) | (78.9) | (91.0) | — |
| Net Income | (266.3) | (299.8) | (299.8) | (172.0) | (1,009.0) | (845.3) | (809.2) | — |
| Per Share | ||||||||
| Basic EPS | (0.37) | (0.43) | (0.43) | (0.24) | (1.42) | (1.26) | — | — |
| Diluted EPS | (0.37) | (0.54) | (0.54) | (0.24) | (1.42) | (1.26) | — | — |
| Revenue per Share | 0.01 | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 720.8 | 693.9 | 693.9 | 725.4 | 712.8 | 669.8 | — | — |
| Diluted Weighted Avg Shares | 720.8 | 693.9 | 693.9 | 725.4 | 712.8 | 669.8 | — | — |
| Supplemental | ||||||||
| EBITDA | — | (511.7) | (511.7) | (989.2) | (887.9) | (1,345.7) | — | — |
| EBIT | (596.1) | (515.1) | (515.1) | (1,003.3) | (906.8) | (1,351.6) | (1,070.9) | — |
| Effective Tax Rate | -43.0% | -50.4% | — | — | -0.5% | -0.0% | -0.2% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.